Toronto, ON, May 14, 2020 – Dr. Rangarajan Sambathkumar, a pioneering young investigator at the University Health Network in Toronto, has been awarded a second post-doctoral fellowship ($60,000) for his stem cell research, based on an ongoing collaboration between JDRF Canada and Eli Lilly Canada Inc. (Lilly Canada).
Health Canada’s authorization to use FreeStyle Libre in Hospitals During COVID-19 Pandemic Positive for Canadians with Diabetes
JDRF Canada, the leading global funder of type 1 diabetes (T1D) research, welcomes Health Canada’s authorization under Interim order to use the FreeStyle® Libre System for hospitalized patients during the COVID-19 Pandemic.
The JDRF – Beyond Type 1 Alliance Releases Recommendations for People with Diabetes During COVID-19 Pandemic
The recommendations are supported by 50 international organizations working together to curb the spread of COVID-19 and protect those most vulnerable.
JDRF Launches Canada’s Largest Virtual House Party to Raise Funds for Diabetes
Toronto, Ontario, April 20, 2020 – In the new reality of physical distancing, JDRF is bringing Canadians together to unite, get loud and raise funds to accelerate the pace of type 1 diabetes research – all from home. The JDRF House ParT1D for a Cure, presented by Omnipod, will take place on Sunday, June 14, 2020, and is Canada’s largest virtual house party turning type one diabetes into type none.
JDRF Calgary cancels in-person “Picks and Plates” Gala in response to Coronavirus Outbrake
Calgary, AB – March, 13 2020 – In response to concerns regarding the global Coronavirus outbreak, JDRF Calgary has cancelled its popular “Picks and Plates” Gala while continuing the event’s online fundraising activities. The in-person event was scheduled to take place April 18 at Hotel Arts.
Finance Committee’s Budget Recommendations Positive for Canadians with Diabetes
Toronto, ON – March 3, 2020 – JDRF Canada, the leading global funder of type 1 diabetes (T1D) research, welcomes the release of the Standing Committee on Finance’s report and its recommendations to address the diabetes epidemic.
JDRF Canada responds to INESS recommendations regarding Dexcom G6 Continuous Glucose Monitor
Toronto, Ontario – February 27, 2020 – JDRF Canada, the leading global funder of type 1 diabetes (T1D) research, is hopeful that the Government of Quebec might still consider provincial coverage for Continuous Glucose Monitoring (CGM) in spite of a report released this month by the Institut national d’excellence en santé et services sociaux (INESS).
Max Domi launches fund to help Canadians living with type 1 diabetes
MONTREAL, October 25, 2019 – Montreal Canadiens centre and JDRF ambassador, Max Domi, unveiled The Max Domi Fund for Type 1 Diabetes today at the Bell Sports Complex.
JDRF welcomes effort to expand Disability Tax Credit eligibility for Canadians with diabetes
TORONTO, October 2nd, 2019 – JDRF welcomes the Conservative announcement yesterday committing to legislation making it easier for Canadians with type 1 diabetes (T1D) and others to qualify for the Disability Tax Credit (DTC).
Interview opportunity: JDRF celebrates the announcement of Dexcom G6 CGM System’s Availability in Canada
JDRF shares the excitement of the type 1 diabetes community around today’s arrival of the Dexcom G6,” said Dave Prowten, President and CEO of JDRF Canada. “While JDRF remains focused on our goal to cure type 1 diabetes, we welcome the arrival of new and innovative technologies like this that help Canadians living with the disease live easier, healthier, safer lives.”
JDRF Canada and Boston Pizza Foundation Future Prospects Award Grants to Canadian Students Living with Type 1 Diabetes
– Inaugural JDRF-led initiative provides grants of $5,000 each for a total of $105,000 to cover tuition and book costs –
Statement by Dave Prowten, President and CEO JDRF Canada
JDRF has been closely monitoring developments rising from the recent announcement of a “Safe Importation Action Plan” by the United States Department of Health & Human Services (HHS) and the Food and Drug Administration (FDA) to facilitate the importation of drugs that were intended for other markets, specifically Canada.